Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of Silexan in adults with mild to moderate major depressive episode
2020-000688-22Phase 3Completed
- Sponsor
- Schwabe Group
- Start
- Aug 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Silexan in major depressive disorder (MDD) (3 arms), sponsored by Schwabe Group. Primary endpoint: Change in MADRS total score from baseline to Week 8. Started Aug 2020; status: completed.
02
Drugs
Silexan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-000688-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000688-22.